Table 5.
VS-4718 did not affect ABCC1-mediated MDR.
| Treatment | IC50 ±SDa (RFb) | |
|---|---|---|
| KB-3-1 (μM) | KB-CV60 (μM) | |
| Vincristine | 0.012 ± 0.001 (1.00) | 0.207 ± 0.011 (17.96) |
| +VS-4718 (1 μM) | 0.013 ± 0.005 (1.09) | 0.203 ± 0.005 (17.68) |
| +VS-4718 (3 μM) | 0.013 ± 0.003 (1.09) | 0.220 ± 0.035 (19.12) |
| +MK 571 (25 μM) | 0.016 ± 0.007 (1.35) | 0.092 ± 0.020 (7.98)* |
| Cisplatin | 1.023 ± 0.275 (1.00) | 1.261 ± 0.218 (1.23) |
| +VS-4718 (1 μM) | 1.015 ± 0.236 (0.99) | 1.381 ± 0.591 (1.35) |
| +VS-4718 (3 μM) | 0.988 ± 0.356 (0.97) | 1.344 ± 0.375 (1.31) |
| +MK 571 (25 μM) | 1.036 ± 0.125 (1.01) | 1.254 ± 0.417 (1.23) |
a
IC50 values were determined by MTT assay as described in “Materials and Methods,” and were obtained from three independent experiments in triplicate.
b
Resistance fold (RF) was calculated from dividing the IC50 values of resistant cells (KB-CV60) by the IC50 of parental cells (KB-3-1) in the presence or absence of VS-4718 or positive control inhibitor.
*
indicates p < 0.05 vs. group treated with antineoplastic drug only.